Navigation Links
Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Date:9/20/2012

MONTREAL, Sept. 20, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (the "Company") announced today that VPI Escrow Corp., a newly formed wholly owned Delaware subsidiary of Valeant Pharmaceuticals International ("Valeant"), a wholly owned indirect subsidiary of the Company, has priced its previously announced offering of $1,750 million aggregate principal amount of 6.375% senior unsecured notes due 2020 (the "Notes"). The offering is expected to close on or about October 4, 2012. The net proceeds of the offering are expected to be used to fund (i) the transactions contemplated by the previously announced Agreement and Plan of Merger ("Merger Agreement") with Medicis Pharmaceutical Corporation ("Medicis") whereby Medicis will continue as a wholly owned subsidiary of Valeant, (ii) Medicis's obligation to pay the conversion consideration with respect to, or repurchase, its outstanding notes, and (iii) transaction expenses in connection with the Merger Agreement.

Additionally, the Company also announced that Valeant has priced its previously announced offering of $500 million aggregate principal amount of 6.375% senior unsecured notes due 2020 (the "Concurrent Notes"). The offering is expected to close on or about October 4, 2012. Valeant intends to use the net proceeds of the offering for general corporate purposes, including potential acquisitions.

The Notes and the Concurrent Notes will be guaranteed by the Company and each of the Company's subsidiaries (other than Valeant) that is a guarantor of the Company and Valeant's senior secured credit facilities.

Neither the Notes nor the Concurrent Notes will be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registrati
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
2. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
3. Valeant Pharmaceuticals To Syndicate Incremental Loans
4. Valeant Pharmaceuticals Announces Management Change
5. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
6. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
7. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
8. Valeant Pharmaceuticals To Host Investor Day
9. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
10. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... BCC Research report discusses the medical device technologies in terms ... and opportunities for different devices and regions. It includes forecasts ... the report focuses on technological trends in recent years in ... and Japan . Use ... device technologies market. - Analyze market structure, including segments and ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... has updated the incredibly successful Serialisation Countdown calendar to ... PDF, available at pharmaserialisation.com shows the serialisation ... they will be coming into force. For ... a matter of "if", but "when" they will have ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Annual Superbugs and Superdrugs Conference on ... ... Enanta Pharmaceuticals, a,leader in the development of small molecule ... to,evaluate a new macrolide-related drug class, Bicyclolides, in the treatment,of ...
... to collaborate on latest research technologies, ALBUQUERQUE, ... Inc. (OTC Bulletin Board: BMOD),( http://www.biomoda.com ), a ... entitled "New Non-Invasive Technology for the Early,Detection of ... Annual,Multidisciplinary Meeting of the American Association for the ...
Cached Medicine Technology:Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 2Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA 3Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting 2
(Date:9/18/2014)... 2014 TayganPoint Consulting Group, a ... President and co-founder John Cassimatis was named as ... for 2014, recognizing the region’s top healthcare and ... executive of the year. , The Innovation Awards ... that continue to shape the medical industry in ...
(Date:9/18/2014)... microbes -- don,t worry, it,s a good thing! As ... microbes are bad. Many active enzymes and bacteria are ... as an important part of our digestive system or ... albicans , an opportunistic yeast pathogen and model organism ... healthy personal ecosystem. However, when our immune system is ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... York, New York (PRWEB) September 18, 2014 ... ) continue to mount in U.S. courts, Bernstein ... has recommended that the U.S. Food & Drug ... new restrictions that, if implemented, could greatly reduce ... Bone, Reproductive and Urologic Drug Advisory Committee, and ...
(Date:9/18/2014)... News) -- Teens and young adults who,ve been mentored ... provides them with greater responsibility and independence early on ... "We found that having a mentor provides a clear ... author, Steve McDonald, an associate professor of sociology at ... release. In conducting the study, published online ...
Breaking Medicine News(10 mins):Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4Health News: Mentors May Steer Young People Toward More Rewarding Careers 2
... approach to treatment that focuses on recovery from mental ... acclaim for the Medical College of Georgia Department of ... Project GREAT, or the Georgia Recovery-Based Educational Approach ... to be part of their own care, while also ...
... FRIDAY, Feb. 24 (HealthDay News) -- Sudden Infant Death Syndrome ... German researchers reports. DNA analysis from a small group ... the male children carried a particular enzyme mutation that may ... the case for female SIDS patients. Study author Dr. ...
... Overweight or obese people with chronic kidney disease may suffer ... new study warns. Cleveland Clinic researchers analyzed the eating ... who took part in the U.S. National Health and Nutrition ... percent said they had tried to lose weight in the ...
... Serena Gordon HealthDay Reporter , FRIDAY, Feb. 24 ... on their own take a companion -- usually a spouse ... office visits, researchers report. And they tend to bring ... health care system with another important member of a patient,s ...
... , This release is available in Spanish ... and the university hospital Virgen de las Nieves in Granada ... toxic than that traditionally used and only targets cancerous tissue. ... efficient cancer postoperative treatment for cases of cancer of the ...
... Cells that die naturally generate a lot of internal debris ... leading to diseases such as lupus., Now Georgia Health Sciences ... a woman,s immune system from attacking a fetus also helps ... such as DNA or joints. , The findings point ...
Cached Medicine News:Health News:Psychiatry program garners national education award 2Health News:Psychiatry program garners national education award 3Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 2Health News:Gene Might Be a Culprit in Sudden Infant Death for Boys 3Health News:Dieting Can Prove Dangerous for Kidney Disease Patients 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 2Health News:Many Elderly Now Bring Companion on Doctor's Visit 3Health News:A new radiotherapy technique significantly reduces irradiation of healthy tissue 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Duckbill type sharp. 3 mm wide x 8 mm long curved blade. Octagonal handle....
9 mm slightly curved blade. Hexagonal handle....
Medicine Products: